drugset / Trial / NCT06431386

Behavioural Activation Therapy and Esketamine for Resistant Depression

NCT06431386

RandomizedParallel-groupSingle-blindTreatment

Summary

This is a randomized clinical trial to test the effectiveness of combining a proven psychological intervention called behavioural activation therapy alongside esketamine treatment for treatment resistant major depressive episodes in individuals with major depressive disorder or bipolar disorder. Encouraging participants to practice new behaviours while their mood is improved through esketamine treatment may lead to more lasting recovery from depression.

Timeline

Start
2024-06-11
Primary completion
2025-09-17
Completion
2025-09-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Esketamine Other / unclassified 56 mg Intranasal
Subject Esketamine Other / unclassified 84 mg Intranasal